Full-length thymosin beta-4, formulated as a topical ophthalmic solution (RGN-259), has been evaluated in genuine Phase II randomized, placebo-controlled human trials for dry eye disease
2 Though theoretically the use of NAD+ via various routes of administration for various conditions is promising, data is primarily limited to case studies at this time
It may be used as a diagnostic measure to identify the cause of the fluid accumulation, for example, infection, gout, or rheumatoid arthritis, or as a therapeutic intervention to relieve pressure and discomfort
They are not intended for human consumption or for diagnosing, treating, curing, or preventing any disease.
CPT 90471 may apply for other injectable vaccines given during the same visit as a COVID shot, but the COVID vaccine itself should use its designated administration code not 90471
PMID 30863034